Newsroom
Sorted by: Latest
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust US Large Cap Core AlphaDEX UCITS ETF 01.09.2026 FEXD.LN IE00BWTNMB87 451,437.00 USD 45,318,992.15 100.388 ...
-
Croma-Pharma Introduces Electronic Instructions for Use Across the saypha® Portfolio
LEOBENDORF, Austria--(BUSINESS WIRE)--Croma-Pharma has introduced electronic Instructions for Use (eIFU) across its saypha® portfolio in markets where applicable regulations permit electronic Instructions for Use to replace printed versions. The transition expands digital access to essential product information for healthcare professionals while reducing the use of printed documentation. Healthcare professionals can access the current approved Instructions for Use by scanning the QR code on the...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Buffer UCITS ETF - October 01.09.2026 FOCT.LN IE0004X8KUG5 100,002.00 USD 2,981,573.15 29.815 ...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust US Large Cap Core AlphaDEX UCITS ETF 01.09.2026 FEX.LN IE00B8X9NW27 1,363,395.00 USD 154,533,692.08 113.345 ...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Buffer UCITS ETF 10% - January 01.09.2026 FJAN.LN IE000MDKBOB3 150,002.00 USD 4,408,438.03 29.389 ...
-
York Space Systems, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - YSS
LOS ANGELES--(BUSINESS WIRE)--York Space Systems, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - YSS...
-
Zoetis to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today announced that Kristin Peck, Chief Executive Officer, and Jay Saccaro, EVP, Chief Financial Officer and Chief Operating Officer, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026 at 1:50 p.m. ET. Interested parties can access the live audio webcast of the presentation by visiting https://investor.zoetis.com/events-presentations. A replay will also be ava...
-
Distribution Solutions Group Announces Acquisition of American Fasteners Corp.
FORT WORTH, Texas--(BUSINESS WIRE)--Distribution Solutions Group, Inc. (NASDAQ: DSGR) ("DSG" or the "Company"), a premier specialty distribution company, today announced the acquisition of American Fasteners Corp. (“American Fasteners”, or “AFC”), a leading South Florida distributor of fasteners, tools, construction supplies and other industrial products.The acquisition strengthens DSG’s MRO business by expanding its customer base and presence in the attractive South Florida market while providi...
-
Encoded Therapeutics to Present New Data on ETX101 Gene Therapy for Dravet Syndrome at the 16th European Epilepsy Congress
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Encoded Therapeutics Inc., a clinical-stage biotechnology company developing precision genetic medicines for severe neurological disorders, today announced that new results from the POLARIS clinical program of ETX101, its investigational AAV9-based gene regulation therapy for SCN1A+ Dravet syndrome, will be featured in a platform presentation at the 16th European Epilepsy Congress on September 7, 2026, in Athens, Greece. Professor Ingrid Scheffer, P...
-
Treeline Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate TLN-121 in Combination with CD20xCD3 T-Cell-Engaging Bispecific Antibodies
WATERTOWN, Mass.--(BUSINESS WIRE)--Treeline Biosciences, Inc. (“Treeline”) today announced a clinical trial collaboration and supply agreement with Roche (SIX: RO, ROP; OTCQX: RHHBY) to evaluate TLN-121, Treeline's BCL6 degrader, in combination with Roche’s CD20xCD3 T-cell-engaging bispecific antibodies glofitamab and mosunetuzumab in separate combination cohorts for patients with B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL). Under the terms of the agreement, Treeline will...